The Vernakalant Story: How Did It Come to Approval in Europe and What is the Delay in the U.S.A?
Author:
- John Camm Md A.JAJohn Camm Md A.
Open Access
- 31 July 2014
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 10 (4) , 309-314
Abstract
The sudden onset of atrial fibrillation (AF) is often associated with rapid irregular palpitations, chest pain, shortness of breath and considerable anxiety. If a patient presents shortly after the onset of the arrhythmia the physician may adopt initially an expectant “wait and see” policy, perhaps with the help of mild sedation and drug therapy to reduce the ventricular rate. If the arrhythmia does not terminate spontaneously and has been present for less than 24-48 hours restoration of sinus rhythm by cardioversion should be considered. This manuscript reviews the option of electrical cardioversion versus pharmacologic and the data for, the role of, and the status of vernakalant with respect to the latter.Keywords
This publication has 20 references indexed in Scilit:
- Pharmacological conversion of recent-onset atrial fibrillation: A systematic reviewScandinavian Cardiovascular Journal, 2012
- The novel Kv1.5 channel blocker vernakalant for successful treatment of new-onset atrial fibrillation in a critically ill abdominal surgical patientBritish Journal of Anaesthesia, 2011
- Vernakalant Selectively Prolongs Atrial Refractoriness With No Effect on Ventricular Refractoriness or Defibrillation Threshold in PigsJournal of Cardiovascular Pharmacology, 2011
- A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial FibrillationJACC, 2011
- Usefulness of Vernakalant Hydrochloride Injection for Rapid Conversion of Atrial FibrillationThe American Journal of Cardiology, 2010
- A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythmAmerican Heart Journal, 2010
- Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac SurgeryCirculation: Arrhythmia and Electrophysiology, 2009
- Vernakalant Hydrochloride for Rapid Conversion of Atrial FibrillationCirculation, 2008
- The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in HumansJournal of Cardiovascular Pharmacology, 2007
- A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillationJACC, 2004